What is the difference between simvastatin and atorvastatin?

Difference Between Simvastatin and Atorvastatin

Atorvastatin is 2 to 4 times more potent than simvastatin at equivalent doses for reducing LDL cholesterol, total cholesterol, and triglycerides, while simvastatin produces greater HDL cholesterol increases, particularly at maximum doses. 1

Potency and LDL-Lowering Efficacy

The key clinical difference lies in lipid-lowering potency, with dose equivalence between atorvastatin and simvastatin ranging from 1:2 to 1:4. 1

• Atorvastatin 10 mg produces significantly greater LDL-C reduction (37.0-37.2%) compared to simvastatin 10 mg (28.9-29.6%) and is comparable to or exceeds simvastatin 20 mg (33.8%) 2, 3
• At starting doses, atorvastatin 10 mg achieves LDL-C reductions similar to simvastatin 20-40 mg 4, 5
• The ASAP trial demonstrated that atorvastatin 80 mg decreased carotid intima-media thickness over 2 years, while simvastatin 40 mg daily resulted in increased carotid IMT in patients with familial hypercholesterolemia 5, 6, 7

HDL Cholesterol Effects

Simvastatin demonstrates superior HDL-raising effects compared to atorvastatin, with the greatest advantage at maximum doses. 8

• Simvastatin 80 mg produces significantly greater HDL-C increases than atorvastatin 80 mg (weighted mean difference of -4.35%; 95% CI, -5.64 to -3.08) 1
• At comparable doses (simvastatin 40-80 mg vs atorvastatin 20-80 mg), simvastatin consistently produces greater increases in HDL cholesterol and apolipoprotein A-I 8
• This HDL advantage occurs without any apparent dose-equivalence point between the two statins 1

Triglyceride Reduction

Atorvastatin produces significantly greater triglyceride reductions than simvastatin at equivalent doses. 2

• Atorvastatin 10 mg reduces triglycerides by 22.1% compared to 16.0% with simvastatin 10 mg (p < 0.0001) 2
• This triglyceride-lowering advantage is consistent across the dose range and represents a 2-4 fold greater potency for atorvastatin 1

Cardiovascular Outcomes

High-dose atorvastatin (80 mg) demonstrates superior cardiovascular event reduction compared to moderate-dose simvastatin in patients with carotid stenosis and acute coronary syndromes. 5, 6, 7

• In patients with carotid stenosis, atorvastatin 80 mg reduced stroke risk by 33% (HR 0.67,95% CI 0.47-0.94; p=0.02), major coronary events by 43% (HR 0.57,95% CI 0.32-1.00; p=0.05), and subsequent carotid revascularization by 56% (HR 0.44,95% CI 0.24-0.79; p=0.006) 5, 6, 7
• The PROVE-IT trial showed atorvastatin 80 mg reduced major cardiovascular events by 16% compared to pravastatin 40 mg in acute coronary syndrome patients 9

Safety Profile Differences

At maximum doses, simvastatin 80 mg carries higher myopathy risk, while atorvastatin 80 mg has higher rates of hepatotoxicity and gastrointestinal side effects. 10, 8

Simvastatin Safety Concerns:

• Simvastatin 80 mg is associated with significantly increased myopathy risk, with the SEARCH trial identifying 53 cases of myopathy with 80 mg versus only 3 cases with 20 mg (relative risk 8.8; 95% CI 4.2-18.4) 10
• The FDA recommends limiting simvastatin to 20 mg daily when combined with amiodarone due to drug interactions 10
• Maximum simvastatin dose should not exceed 40 mg when combined with amlodipine, and 10 mg when combined with verapamil or diltiazem 11

Atorvastatin Safety Concerns:

• Atorvastatin 80 mg produces a 6-fold increase in liver enzyme elevations (1.2% vs 0.2% with 10 mg; p < 0.001) 12
• At maximum doses, atorvastatin 80 mg has approximately 2-fold higher incidence of drug-related adverse events compared to simvastatin 80 mg (23% vs 12%, p < 0.001), predominantly gastrointestinal symptoms (10% vs 3%, p < 0.001) 8
• Clinically significant ALT elevations occur more frequently with atorvastatin 80 mg (3.8% vs 0.5% with simvastatin 80 mg, p < 0.010), especially in women (6.0% vs 0.6%) 8

Dosing Equivalence for Clinical Practice

When switching between statins, use a 1:2 to 1:4 dose ratio (atorvastatin:simvastatin) to achieve comparable LDL-lowering effects. 1

• Atorvastatin 10 mg ≈ Simvastatin 20-40 mg for LDL reduction 4, 3
• Atorvastatin 20 mg ≈ Simvastatin 40-80 mg for LDL reduction 4
• The American College of Cardiology recognizes simvastatin 40 mg, pravastatin 40 mg, and atorvastatin 10 mg as having solid documentation for cardiovascular risk reduction 12

Drug Interaction Considerations

Simvastatin has more clinically significant drug interactions due to extensive CYP3A4 metabolism, requiring dose limitations with multiple commonly prescribed cardiovascular medications. 10

• Simvastatin requires dose restrictions with amiodarone (≤20 mg), amlodipine (≤20 mg), verapamil (≤10 mg), and diltiazem (≤10 mg) 10, 11
• Atorvastatin, while also metabolized by CYP3A4, has fewer dose restrictions with these agents, though caution is still warranted 10

Clinical Decision Algorithm

Choose atorvastatin when:

• Maximum LDL-lowering is the primary goal 1, 2
• Significant triglyceride reduction is needed 2
• Patient requires aggressive cardiovascular risk reduction (use 80 mg dose) 5, 6, 7
• Patient is on medications that interact with simvastatin (amiodarone, calcium channel blockers) 10

Choose simvastatin when:

• HDL elevation is a priority alongside LDL reduction 1, 8
• Moderate-intensity statin therapy is appropriate (40 mg dose has strong outcomes data) 12
• Cost considerations favor generic simvastatin
• Patient is elderly or frail (avoid 80 mg dose due to myopathy risk) 13, 10